Condition (MeSH)
Stiff-Person Syndrome
ClinicalTrials.gov lists 20 trials for Stiff-Person Syndrome or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Stiff-Person Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Stiff-Person Syndrome trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 2 |
| 2024 | 4 |
| 2022 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2014 | 1 |
| 2008 | 1 |
| 2004 | 1 |
| 2002 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Stiff-Person Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 6 |
How many Stiff-Person Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 6 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Stiff-Person Syndrome trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 3 |
| Kyverna Therapeutics | 2 |
| Adicet Therapeutics | 1 |
| CRISPR Therapeutics | 1 |
| Kedrion S.p.A. | 1 |
Which drugs are being tested for Stiff-Person Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 2 |
| Cytoxan | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Intravenous Immunoglobulins, Human | 1 |
| Standard Lymphodepletion regimen | 1 |
| Cytarabine IT | 1 |
| Autologous Hematopoietic Stem Cell Transplantation | 1 |
| CTX112 | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Stiff-Person Syndrome trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Non Treatment Related Death | 1 | 1 |
Which publications cover Stiff-Person Syndrome? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology. | Neurology(R) neuroimmunology & neuroinflammation | 2023 | Yes |
| Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial. | Neurology | 2021 | Yes |
| Stiff person syndrome. | Frontiers of neurology and neuroscience | 2009 | Yes |
| Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. | Neurology | 2001 | Yes |
| The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. | Neurology | 2000 | Yes |
Showing 5 of 9 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Stiff person spectrum disorder | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Stiff person spectrum disorder | Point prevalence | <1 / 1 000 000 | Tanzania, United Republic of | Not stated | Unspecified |
| Stiff person spectrum disorder | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.